According to Stock Talk (@stocktalkweekly), Bank of America has reiterated its 'Underperform' rating on Hims & Hers Health ($HIMS) with a $28 price target due to a reported total sales decline in April, as cited by analyst Michael Cherny. This downgrade and sales weakness may signal increased risk sentiment for growth stocks, which could influence crypto market positioning, as traders often rotate between tech equities and digital assets based on risk appetite (source: Stock Talk on Twitter, May 22, 2025).